ACHIEVE-4, the longest Phase 3 study of Eli Lilly's (LLY) Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
- FDA submission planned by end-Q2.
Context
Eli Lilly's Phase 3 study results for Foundayo reaffirm its cardiovascular safety and cardiometabolic health, which supports its future FDA submission. This positive outcome could enhance investor confidence and drive valuation, especially in light of competitive pressures in the pharmaceuticals sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES